1-heptyl-1-thio-α,β-D-glucopyranoside | 135969-76-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-heptyl-1-thio-α,β-D-glucopyranoside
• 英文别名: (3R,4S,5S,6R)-2-heptylsulfanyl-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 135969-76-5
• 化学式: C₁₃H₂₆O₅S
• 分子量: 294.412
• InChiKey: HPEGNLMTTNTJSP-HENWMNBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  115
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-heptyl-1-thio-α,β-D-glucopyranoside 生成 1-heptylthio-1-deoxy-D-glucitol
  参考文献：
  名称：

  Dahlhoff, Wilhelm V., Liebigs Annalen der Chemie, 1990, # 10, p. 1025 - 1027

  摘要：

  DOI：
• 作为产物：
  描述：

  1-庚硫醇 在 三氟化硼乙醚 、 sodium methylate 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 0.17h， 生成 1-heptyl-1-thio-α,β-D-glucopyranoside
  参考文献：
  名称：

  Dahlhoff, Wilhelm V., Liebigs Annalen der Chemie, 1990, # 10, p. 1025 - 1027

  摘要：

  DOI：

文献信息

• [EN] PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS<br/>[FR] PEPTIDOMIMÉTIQUES POUR LE TRAITEMENT D'INFECTIONS PAR CORONAVIRUS ET PICORNAVIRUS
  申请人：UNIV EMORY

  公开号：WO2020247665A1

  公开（公告）日：2020-12-10

  Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or Hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV- 2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

  用于预防、治疗或治愈人类主体或其他动物宿主中的冠状病毒、小RNA病毒和/或肝炎病毒感染的化合物、组合物和方法。可治疗的特定病毒包括肠病毒。在一个实施例中，这些化合物可用于治疗严重急性呼吸综合征病毒感染，如人类冠状病毒229E、SARS、MERS、SARS-CoV-1（OC43）和SARS-CoV-2。在另一个实施例中，这些方法用于治疗患有两种或更多这些病毒的患者，或一种或多种这些病毒与诺如病毒的组合。
• SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA
  申请人：PROTIVA BIOTHERAPEUTICS, INC.

  公开号：US20160115483A1

  公开（公告）日：2016-04-28

  The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to silence PLK-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence PLK-1 expression and methods of use thereof. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) comprising an interfering RNA molecule described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing PLK-1 gene expression by administering an interfering RNA molecule described herein to a mammalian subject. The present invention additionally provides methods of identifying and/or modifying PLK-1 interfering RNA having immunostimulatory properties. Methods for sensitizing a cell such as a cancer cell to the effects of a chemotherapy drug comprising sequentially delivering PLK-1 interfering RNA followed by the chemotherapy drug are also provided.

  本发明提供了包含干扰RNA（例如siRNA、aiRNA、miRNA）的组合物，其靶向波洛样激酶1（PLK-1）表达，并提供了使用这种组合物来沉默PLK-1表达的方法。更具体地说，本发明提供了未修饰和化学修饰的干扰RNA分子，这些分子可以沉默PLK-1表达，并提供了它们的使用方法。本发明还提供了含有干扰RNA分子、阳离子脂质和非阳离子脂质的血清稳定核酸-脂质颗粒（例如SNALP），这些颗粒还可以进一步包含抑制颗粒聚集的共轭脂质。本发明还提供了通过向哺乳动物主体施用本文描述的干扰RNA分子来沉默PLK-1基因表达的方法。本发明还提供了识别和/或修改具有免疫刺激性能的PLK-1干扰RNA的方法。此外，还提供了一种通过顺序输送PLK-1干扰RNA后接着化疗药物来使细胞（如癌细胞）对化疗药物产生敏感性的方法。
• [EN] PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION<br/>[FR] PEPTIDOMIMÉTIQUES POUR LE TRAITEMENT D'UNE INFECTION À NOROVIRUS
  申请人：UNIV EMORY

  公开号：WO2017197377A1

  公开（公告）日：2017-11-16

  The present invention is directed to compounds, compositions and methods for preventing, treating or curing Norovirus infection in human subjects or other animal hosts.

  本发明涉及用于预防、治疗或治愈人类主体或其他动物宿主中的诺如病毒感染的化合物、组合物和方法。
• [EN] ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS<br/>[FR] ÉLIMINATION DU VIRUS DE L'HÉPATITE B PAR DES AGENTS ANTIVIRAUX
  申请人：UNIV EMORY

  公开号：WO2017156255A1

  公开（公告）日：2017-09-14

  The present invention is directed to compounds, compositions and methods for preventing, treating or curing Hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.

  本发明涉及用于预防、治疗或治愈人类或其他动物宿主体内乙型肝炎（HBV）感染的化合物、组合物和方法。这些化合物还包括作为药用的可接受的盐、前药和其他衍生物，以及用于治疗、预防或根除HBV感染的药物组合物和方法。
• Methods of treating diseases responsive to Induction of Apoptosis
  申请人：Kasibhatla Shailaja

  公开号：US20050004005A1

  公开（公告）日：2005-01-06

  The present invention pertains to a method of treating, preventing or ameliorating a disease responsive to induction of the caspase cascade in an animal, comprising administering to the animal a compound which binds specifically to a Tail Interacting Protein Related Apoptosis Inducing Protein (TIPRAIP). The present invention also relates to screening methods useful for drug discovery of apoptosis inducing compounds. In particular, the screening methodology relates to using TIPRAIP as a target for the discovery of apoptosis activators useful as anticancer agents. The screening methods of the present invention can employ homogenous or heterogenous binding assays using purified or partially purified TIPRAIP; or whole cell assays using cells with altered levels of TIPRAIP. The invention also contemplates use of 3-(4-azidophenyl)-5-(3-chloro-thiophen-2-yl)-[1,2,4]-oxadiazole or a substituted 3-aryl-5-aryl-[1,2,4]-oxadiazole which bind TIPRAIP and can accordingly be used to raise antibodies useful for drug discovery. Alternatively, labeled 3-(4-azidophenyl)-5-(3-chloro-thiophen-2-yl)-[1,2,4]-oxadiazole (or a labeled substituted 3-aryl-5-aryl-[1,2,4]-oxadiazole) is used for competitive binding assays for drug discovery. Such assays afford high throughput screening of chemical libraries for apoptosis activators.

  本发明涉及一种用于治疗、预防或改善对Caspase级联诱导敏感的动物疾病的方法，包括向动物投药一种与尾部相互作用蛋白相关凋亡诱导蛋白（TIPRAIP）特异结合的化合物。本发明还涉及有用于药物发现凋亡诱导化合物的筛选方法。特别是，筛选方法涉及使用TIPRAIP作为靶标，以发现作为抗癌剂有用的凋亡激活剂。本发明的筛选方法可以采用使用纯化或部分纯化的TIPRAIP的均相或异相结合分析；或使用具有改变TIPRAIP水平的细胞的全细胞分析。本发明还考虑使用3-（4-偶氮苯基）-5-（3-氯噻吩-2-基）-[1,2,4]-噁二唑或结合TIPRAIP的取代3-芳基-5-芳基-[1,2,4]-噁二唑，可用于制备有用于药物发现的抗体。或者，标记的3-（4-偶氮苯基）-5-（3-氯噻吩-2-基）-[1,2,4]-噁二唑（或标记的取代的3-芳基-5-芳基-[1,2,4]-噁二唑）可用于药物发现的竞争结合分析。这种分析为化学文库的高通量筛选提供了凋亡激活剂。